Toxin and Immunotoxin Based Therapeutic Approaches / / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi.

In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied anti...

Full description

Saved in:
Bibliographic Details
TeilnehmendeR:
Place / Publishing House:Basel : : MDPI - Multidisciplinary Digital Publishing Institute,, 2022.
Year of Publication:2022
Language:English
Physical Description:1 online resource (122 pages)
Tags: Add Tag
No Tags, Be the first to tag this record!
id 993562204504498
ctrlnum (CKB)4920000001372300
(NjHacI)994920000001372300
(EXLCZ)994920000001372300
collection bib_alma
record_format marc
spelling Toxin and Immunotoxin Based Therapeutic Approaches / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi.
Basel : MDPI - Multidisciplinary Digital Publishing Institute, 2022.
1 online resource (122 pages)
text txt rdacontent
computer c rdamedia
online resource cr rdacarrier
Description based on online resource; title from PDF title page (MDPI - Multidisciplinary Digital Publishing Institute, viewed February 24, 2023).
In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments. A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity. This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo.
Clinical medicine.
3-0365-3065-7
Bolognesi, Andrea, editor.
Polito, Letizia, editor.
Bortolotti, Massimo, editor.
language English
format eBook
author2 Bolognesi, Andrea,
Polito, Letizia,
Bortolotti, Massimo,
author_facet Bolognesi, Andrea,
Polito, Letizia,
Bortolotti, Massimo,
author2_variant a b ab
l p lp
m b mb
author2_role TeilnehmendeR
TeilnehmendeR
TeilnehmendeR
title Toxin and Immunotoxin Based Therapeutic Approaches /
spellingShingle Toxin and Immunotoxin Based Therapeutic Approaches /
title_full Toxin and Immunotoxin Based Therapeutic Approaches / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi.
title_fullStr Toxin and Immunotoxin Based Therapeutic Approaches / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi.
title_full_unstemmed Toxin and Immunotoxin Based Therapeutic Approaches / edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi.
title_auth Toxin and Immunotoxin Based Therapeutic Approaches /
title_new Toxin and Immunotoxin Based Therapeutic Approaches /
title_sort toxin and immunotoxin based therapeutic approaches /
publisher MDPI - Multidisciplinary Digital Publishing Institute,
publishDate 2022
physical 1 online resource (122 pages)
isbn 3-0365-3065-7
callnumber-first R - Medicine
callnumber-subject RC - Internal Medicine
callnumber-label RC48
callnumber-sort RC 248 T695 42022
illustrated Not Illustrated
dewey-hundreds 600 - Technology
dewey-tens 610 - Medicine & health
dewey-ones 616 - Diseases
dewey-full 616
dewey-sort 3616
dewey-raw 616
dewey-search 616
work_keys_str_mv AT bolognesiandrea toxinandimmunotoxinbasedtherapeuticapproaches
AT politoletizia toxinandimmunotoxinbasedtherapeuticapproaches
AT bortolottimassimo toxinandimmunotoxinbasedtherapeuticapproaches
status_str n
ids_txt_mv (CKB)4920000001372300
(NjHacI)994920000001372300
(EXLCZ)994920000001372300
carrierType_str_mv cr
is_hierarchy_title Toxin and Immunotoxin Based Therapeutic Approaches /
author2_original_writing_str_mv noLinkedField
noLinkedField
noLinkedField
_version_ 1764993888930496512
fullrecord <?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>02499nam a2200301 i 4500</leader><controlfield tag="001">993562204504498</controlfield><controlfield tag="005">20230225102143.0</controlfield><controlfield tag="006">m o d </controlfield><controlfield tag="007">cr |||||||||||</controlfield><controlfield tag="008">230225s2022 sz o 000 0 eng d</controlfield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(CKB)4920000001372300</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(NjHacI)994920000001372300</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(EXLCZ)994920000001372300</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">NjHacI</subfield><subfield code="b">eng</subfield><subfield code="e">rda</subfield><subfield code="c">NjHacl</subfield></datafield><datafield tag="050" ind1=" " ind2="4"><subfield code="a">RC48</subfield><subfield code="b">.T695 2022</subfield></datafield><datafield tag="082" ind1="0" ind2="4"><subfield code="a">616</subfield><subfield code="2">23</subfield></datafield><datafield tag="245" ind1="0" ind2="0"><subfield code="a">Toxin and Immunotoxin Based Therapeutic Approaches /</subfield><subfield code="c">edited by Massimo Bortolotti, Letizia Polito, Andrea Bolognesi.</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="a">Basel :</subfield><subfield code="b">MDPI - Multidisciplinary Digital Publishing Institute,</subfield><subfield code="c">2022.</subfield></datafield><datafield tag="300" ind1=" " ind2=" "><subfield code="a">1 online resource (122 pages)</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">computer</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">online resource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="588" ind1=" " ind2=" "><subfield code="a">Description based on online resource; title from PDF title page (MDPI - Multidisciplinary Digital Publishing Institute, viewed February 24, 2023).</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">In 1900, Paul Ehrlich, who was studying ricin and abrin at the time, discovered antibodies and paved the way for immunotherapy. After 120 years, Ehrlich's insight into the therapeutic potential of immunotargeting is still a source of inspiration for many scientists. One of the most studied antibody-based targeting strategies is the carrying of powerful toxins. The generated molecules are immunotoxins, i.e., chimeric proteins obtained by coupling bacterial or plant toxins and antibodies through chemical linking or genetic engineering. Immunotoxins are functionally designed to eliminate the cells responsible for pathological conditions, and they find applications in several fields, ranging from cancer to immunological diseases or pain control. Despite the lack of specificity, even native toxins find clinical application, but the use of unconjugated toxins is limited to loco-regional treatments. A fundamental requirement for the medical application of toxins and their immunoconjugates is in-depth knowledge of their interaction with target cells in terms of binding, uptake, intracellular routing, and substrate specificity. This Special Issue focuses on toxins and immunotoxins that have clinical potential. We hope to give the reader a comprehensive overview of new toxin delivery strategies and toxin-based experimental disease models, both in vitro and in vivo.</subfield></datafield><datafield tag="650" ind1=" " ind2="0"><subfield code="a">Clinical medicine.</subfield></datafield><datafield tag="776" ind1=" " ind2=" "><subfield code="z">3-0365-3065-7</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bolognesi, Andrea,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Polito, Letizia,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Bortolotti, Massimo,</subfield><subfield code="e">editor.</subfield></datafield><datafield tag="906" ind1=" " ind2=" "><subfield code="a">BOOK</subfield></datafield><datafield tag="ADM" ind1=" " ind2=" "><subfield code="b">2023-03-01 01:51:15 Europe/Vienna</subfield><subfield code="f">system</subfield><subfield code="c">marc21</subfield><subfield code="a">2022-09-22 08:09:39 Europe/Vienna</subfield><subfield code="g">false</subfield></datafield><datafield tag="AVE" ind1=" " ind2=" "><subfield code="P">DOAB Directory of Open Access Books</subfield><subfield code="x">https://eu02.alma.exlibrisgroup.com/view/uresolver/43ACC_OEAW/openurl?u.ignore_date_coverage=true&amp;portfolio_pid=5338227780004498&amp;Force_direct=true</subfield><subfield code="Z">5338227780004498</subfield><subfield code="8">5338227780004498</subfield></datafield></record></collection>